CoChat

Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases

Open access
Hölscher, Christian · 2022 · Frontiers in Synaptic Neuroscience
Cited by 48

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are peptide hormones and growth factors. A major pathological feature of both Alzheimer’s dis-ease (AD) and Parkinson’s disease (PD) is the loss of synaptic transmission in the cortex in AD and the loss of dopaminergic synapses in the nigra-striatal dopaminergic projection. Several studies demonstrate that GLP-1 and GIP receptor agonists protect synapses and synaptic transmission from the toxic events that underlie AD and PD. In a range of AD animal models, treatment with GLP-1, GIP, or dual-GLP-1/GIP receptor agonists effectively protected cognition, synaptic trans-mission, long-term potentiation (LTP), and prevented the loss of synapses and neurons. In PD models, dopaminergic production resumed and synapses became functional again. Importantly, the GLP-1 receptor agonists exendin-4 and liraglutide have shown good protective effects in clinical trials in AD and PD patients. Studies show that growth factors and peptide drugs that can cross the blood–brain barrier (BBB) better are more potent than those that do not cross the BBB. We therefore developed dual-GLP-1/GIP receptor agonists that can cross the BBB at an enhanced rate and showed superior protective properties on synapses in animal models of AD and PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnsyn.2022.955258

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 82

  1. Abbas, 2009, Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer’s disease., Behav. Brain Res., 205, 265, 10.1016/j.bbr.2009.06.035 · DOI · Paper page
  2. Athauda, 2018, Protective effects of the GLP-1 mimetic exendin-4 in Parkinson’s disease., Neuropharmacology, 136, 260, 10.1016/j.neuropharm.2017.09.023 · DOI · Paper page
  3. Athauda, Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with parkinson disease: a secondary analysis of the Exenatide-PD trial., JAMA Neurol., 76, 420, 10.1001/jamaneurol.2018.4304 · DOI · Paper page
  4. Athauda, Post hoc analysis of the Exenatide-PD trial-Factors that predict response., Eur. J. Neurosci., 49, 410, 10.1111/ejn.14096 · DOI · Paper page
  5. Aviles-Olmos, 2014, Motor and cognitive advantages persist 12 months after exenatide exposure in parkinson’s disease., J. Parkinson’s Dis., 4, 337, 10.3233/JPD-140364 · DOI · Paper page
  6. Bagetta, 2010, Synaptic dysfunction in Parkinson’s disease., Biochem. Soc. Trans., 38, 493, 10.1042/BST0380493 · DOI · Paper page
  7. Blurton-Jones, 2009, Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease., Proc. Natl. Acad. Sci. U. S. A., 106, 13594, 10.1073/pnas.0901402106 · DOI · Paper page
  8. Bove, 2012, Neurotoxin-based models of Parkinson’s disease., Neuroscience, 211, 51, 10.1016/j.neuroscience.2011.10.057 · DOI · Paper page
  9. Bradbury, 2005, Hope for AD with NGF gene-therapy trial., Lancet Neurol., 4, 10.1016/S1474-4422(05)70086-7 · DOI
  10. Cai, 2014, Lixisenatide rescues spatial memory and synaptic plasticity from amyloid beta protein-induced impairments in rats., Neuroscience, 277, 6, 10.1016/j.neuroscience.2014.02.022 · DOI
  11. Cai, 2021, A GLP-1/GIP dual receptor agonist DA4-JC effectively attenuates cognitive impairment and pathology in APP/PS1/tau mice of Alzheimer’s disease., J. Alzheimer’s Dis., 83, 799, 10.3233/JAD-210256 · DOI · Paper page
  12. Cao, 2016, A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brain., Neuroreport, 37, 384, 10.1097/WNR.0000000000000548 · DOI · Paper page
  13. Cao, 2018, DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer’s disease., Eur. J. Pharmacol., 827, 215, 10.1016/j.ejphar.2018.03.024 · DOI
  14. Clarris, 1994, Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer’s disease from hippocampal explants., J. Neurosci. Res., 38, 248, 10.1002/jnr.490380303 · DOI · Paper page
  15. Cork, 2015, Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain., Mol. Metab., 4, 718, 10.1016/j.molmet.2015.07.008 · DOI · Paper page
  16. Covaceuszach, 2009, Development of a non invasive NGF-based therapy for Alzheimer’s disease., Curr. Alz. Res., 6, 158, 10.2174/156720509787602870 · DOI · Paper page
  17. Doyle, 2007, Mechanisms of action of glucagon-like peptide 1 in the pancreas., Pharmacol. Ther., 113, 546, 10.1016/j.pharmthera.2006.11.007 · DOI · Paper page
  18. Duffy, 2013, The incretin analogue D-Ala(2)GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s disease., Neuroscience, 228, 294, 10.1016/j.neuroscience.2012.10.045 · DOI
  19. Edison, 2020, Evaluating the Effects of the Novel GLP-1 Analogue Liraglutide in Alzheimer’s Disease (ELAD Study).
  20. Faivre, D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer’s disease mouse model., J. Alzheimer’s Dis., 35, 267, 10.3233/JAD-121888 · DOI · Paper page
  21. Faivre, Neuroprotective effects of D-Ala2GIP on Alzheimer’s disease biomarkers in an APP/PS1 mouse model., Alz. Res. Ther., 5, 20, 10.1186/alzrt174 · DOI · Paper page
  22. Faivre, 2011, Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis., J. Neurophysiol., 105, 1574, 10.1152/jn.00866.2010 · DOI · Paper page
  23. Femminella, 2019, Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)., Trials, 20, 10.1186/s13063-019-3259-x · DOI · Paper page
  24. Femminella, 2020, Correction to: evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)., Trials, 21, 10.1186/s13063-020-04608-4 · DOI
  25. Feng, 2018, Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson’s disease., Neuropharmacology, 133, 385, 10.1016/j.neuropharm.2018.02.012 · DOI
  26. Foltynie, 2020, Repurposing anti-diabetic drugs for the treatment of Parkinson’s disease: rationale and clinical experience., Prog. Brain Res., 252, 493, 10.1016/bs.pbr.2019.10.008 · DOI · Paper page
  27. Gault, GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid., Eur. J. Pharmacol., 587, 112, 10.1016/j.ejphar.2008.03.025 · DOI
  28. Gault, Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid., J. Neurophysiol., 99, 1590, 10.1152/jn.01161.2007 · DOI · Paper page
  29. Gengler, 2012, Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice., Neurobiol. Aging, 33, 265, 10.1016/j.neurobiolaging.2010.02.014 · DOI · Paper page
  30. Gilman, 2003, Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons., J. Neurochem., 87, 1137, 10.1046/j.1471-4159.2003.02073.x · DOI · Paper page
  31. Graham, 2020, A novel mouse model of glucagon-like peptide-1 receptor expression: a look at the brain., J. Comparat. Neurol., 528, 2445, 10.1002/cne.24905 · DOI · Paper page
  32. Green, 2004, Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid., Arch. Biochem. Biophys., 428, 136, 10.1016/j.abb.2004.05.005 · DOI
  33. Han, 2013, Liraglutide protects against ß-amyloid induced impairment of spatial learning and memory in rats., Neurobiol. Aging, 32, 576, 10.1016/j.neurobiolaging.2012.04.009 · DOI
  34. Hedrington, 2018, Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes., Exp. Opin. Biol. Ther., 18, 343, 10.1080/14712598.2018.1439014 · DOI · Paper page
  35. Heese, 2006, Nerve growth factor, neural stem cells and Alzheimer’s disease., Neurosignals, 15, 1, 10.1159/000094383 · DOI · Paper page
  36. Hölscher, 2014, Insulin, incretins and other growth factors as potential novel treatments for Alzheimer’s and Parkinson’s diseases., Biochem. Soc. Trans., 42, 593, 10.1042/BST20140016 · DOI · Paper page
  37. Hölscher, 2018, Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer’s and Parkinson’s disease models., Neuropharmacol, 136, 251, 10.1016/j.neuropharm.2018.01.040 · DOI · Paper page
  38. Hölscher, 2022, Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders., Br. J. Pharmacol., 179, 695, 10.1111/bph.15508 · DOI · Paper page
  39. Jalewa, 2016, Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells., J. Neurochem., 139, 55, 10.1111/jnc.13736 · DOI · Paper page
  40. Jalewa, 2017, A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson’s disease., Neuropharmacology, 117, 238, 10.1016/j.neuropharm.2017.02.013 · DOI
  41. Ji, 2016, A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson’s disease by increasing expression of BDNF., Brain Res., 1634, 1, 10.1016/j.brainres.2015.09.035 · DOI
  42. Kastin, 2003, Entry of exendin-4 into brain is rapid but may be limited at high doses., Int. J. Obesity Related Metabol. Disord., 27, 313, 10.1038/sj.ijo.0802206 · DOI · Paper page
  43. Kells, 2012, Glial-derived neurotrophic factor gene transfer for Parkinson’s disease: anterograde distribution of AAV2 vectors in the primate brain., Neurobiol. Dis., 48, 228, 10.1016/j.nbd.2011.10.004 · DOI · Paper page
  44. Kordower, 2013, Trophic factor gene therapy for Parkinson’s disease., Movem. Disord., 28, 96, 10.1002/mds.25344 · DOI · Paper page
  45. Kordower, 1997, Cellular delivery of NGF does not alter the expression of beta-amyloid immunoreactivity in young or aged nonhuman primates., Exp. Neurol., 145, 586, 10.1006/exnr.1997.6492 · DOI
  46. Langston, 1983, Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis., Science, 219, 979, 10.1126/science.6823561 · DOI · Paper page
  47. Leech, 1997, Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin., J. Biol. Chem., 272, 17987, 10.1074/jbc.272.29.17987 · DOI · Paper page
  48. Li, 2020, The novel GLP-1/GIP Analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD., Brain Behav., 10, 10.1002/brb3.1505 · DOI · Paper page
  49. Li, 2016, Neuroprotective role of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson’s disease., Neural. Regen. Res., 11, 326, 10.4103/1673-5374.177742 · DOI
  50. Li, 2016, Neuroprotective effects of a GIP analogue in the MPTP Parkinson’s disease mouse model., Neuropharmacology, 101, 255, 10.1016/j.neuropharm.2015.10.002 · DOI
  51. Lin, 1993, GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons., Science, 260, 1130, 10.1126/science.8493557 · DOI · Paper page
  52. Lv, 2021, The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-kappaB inflammatory pathway in the MPTP mouse model of Parkinson’s disease more effectively than the GLP-1 single-receptor agonist NLY01., Brain Behav., 11, 10.1002/brb3.2231 · DOI · Paper page
  53. Malatt, 2022, Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson’s disease: A Randomized, Double-Blind, Placebo-Controlled Trial.
  54. Maskery, 2020, The dual GLP-1/GIP 0gonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP/PS1 mouse model of Alzheimer’s disease, Am. J. Alzheimers Dis. Other Demen, 35, 10.1177/1533317520953041 · DOI · Paper page
  55. Mandel, 2010, CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer’s disease., Curr. Opin. Mol. Ther., 12, 240
  56. McClean, Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease., Neuropharmacology, 76, 57, 10.1016/j.neuropharm.2013.08.005 · DOI · Paper page
  57. McClean, 2015, Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice., Behav. Brain Res., 293, 96, 10.1016/j.bbr.2015.07.024 · DOI
  58. Merchenthaler, 1999, Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system., J. Comparat. Neurol., 403, 261, 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5 · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
  59. Migliore, 2014, Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson’s disease., Neuroscience, 274, 11, 10.1016/j.neuroscience.2014.05.019 · DOI
  60. Mueller, 2008, Clinical gene therapy using recombinant adeno-associated virus vectors., Gene. Ther., 15, 858, 10.1038/gt.2008.68 · DOI · Paper page
  61. Oka, Glucagon-like peptide-1 modulates neuronal activity in the rat’s hippocampus., Neuroreport, 10, 1643, 10.1097/00001756-199906030-00004 · DOI · Paper page
  62. Oka, Endogenous GLP-1 modulates hippocampal activity in beta-amyloid protein-treated rats., Neuroreport, 10, 2961, 10.1097/00001756-199909290-00016 · DOI
  63. Panagaki, 2018, The novel DA3-CH dual incretin restores endoplasmic reticulum stress and autophagy impairments to attenuate Alzheimer-Like pathology and cognitive decrements in the APPSWE/PS1DeltaE9 mouse model., J. Alzheimer’s Dis., 66, 195, 10.3233/JAD-180584 · DOI · Paper page
  64. Picconi, 2012, Synaptic dysfunction in Parkinson’s disease., Adv. Exp. Med. Biol., 970, 553, 10.1007/978-3-7091-0932-8_24 · DOI · Paper page
  65. Picconi, 2005, Pathological synaptic plasticity in the striatum: implications for Parkinson’s disease., Neurotoxicology, 26, 779, 10.1016/j.neuro.2005.02.002 · DOI
  66. Poon, 2009, beta-Amyloid impairs axonal BDNF retrograde trafficking., Neurobiol. Aging, 39, 821, 10.1016/j.neurobiolaging.2009.05.012 · DOI · Paper page
  67. Rafii, 2014, A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer’s disease., Alzheimer’s Dement., 10, 571, 10.1016/j.jalz.2013.09.004 · DOI · Paper page
  68. Schulte-Herbruggen, 2007, Neurotrophic factors–a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases?, Curr. Med. Chem., 14, 2318, 10.2174/092986707781745578 · DOI · Paper page
  69. Shi, 2017, A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model., Behav. Brain Res., 327, 65, 10.1016/j.bbr.2017.03.032 · DOI
  70. Suzuki, 1997, Localization of the ATP-sensitive K+ channel subunit Kir6.2 in mouse pancreas., Diabetes, 46, 1440, 10.2337/diab.46.9.1440 · DOI · Paper page
  71. Talbot, 2011, The Diabetes Drug Liraglutide Ameliorates Insulin Resistance in the Hippocampal Formation of Alzheimer Disease (AD) Cases., 10.1016/j.jalz.2011.09.137 · DOI
  72. Usdin, 1993, Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain., Endocrinology, 133, 2861, 10.1210/endo.133.6.8243312 · DOI · Paper page
  73. Van Laar, 2021, An update on gene therapy approaches for Parkinson’s Disease: restoration of dopaminergic function., J. Parkinson’s Dis., 11, S173, 10.3233/JPD-212724 · DOI
  74. Verma, 2017, Effect of D-Ala2GIP, a stable GIP receptor agonist on MPTP-induced neuronal impairments in mice., Eur. J. Pharmacol., 804, 38, 10.1016/j.ejphar.2017.03.059 · DOI
  75. Wang, 2019, DA-JC1 improves learning and memory by antagonizing Abeta31-35-induced circadian rhythm disorder., Mol. Brain, 12, 10.1186/s13041-019-0432-9 · DOI
  76. Wang, 2013, Val(8)-GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid beta peptide in rats., J. Neurosci. Res., 91, 568, 10.1002/jnr.23181 · DOI
  77. Wheeler, 1994, Roles of N-type and Q-type Ca2+ channels in supporting hippocampal synaptic transmission., Science, 264, 107, 10.1126/science.7832825 · DOI · Paper page
  78. Winder, 1993, Activation of metabotropic glutamate receptors increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine., J. Neurosci., 13, 38, 10.1523/JNEUROSCI.13-01-00038.1993 · DOI · Paper page
  79. Yuan, 2017, A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson’s disease., Eur. J. Pharmacol., 812, 82, 10.1016/j.ejphar.2017.06.029 · DOI
  80. Zhang, 2020, The novel dual GLP-1/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson’s disease., J. Parkinson Dis., 10, 523, 10.3233/JPD-191768 · DOI · Paper page
  81. Zhang, 2015, Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson’s disease mouse model., Behav. Brain Res., 293, 107, 10.1016/j.bbr.2015.07.021 · DOI
  82. Zhang, 2020, GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models., Peptides, 125, 10.1016/j.peptides.2019.170184 · DOI · Paper page

Cited by

Metadata

Authors
Hölscher, C.
Venue
Frontiers in Synaptic Neuroscience
Published
2022-07-27
Volume
14
Pages
955258-955258
ISSN
1663-3563 (ISSN-L)
OpenAlex
W4288033440
Cited by
48
References
30
FWCI
4.88
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.